Oracle Runs

Oracle findings and outcome history for Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns (NCT07025408).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial listed as Recruiting on ClinicalTrials.gov with estimated primary completion Mar 2026. Sponsor docs confirm Phase II ongoing, expect completion H1 2026. No public results or readout available as of Apr 2026.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM

ClinicalTrialsclinicaltrials.gov

Phase II Clinical Trial of KJ101 in the Treatment of Deep II Degree Burns

Current Status: Recruiting. Estimated Primary Completion Date: March 18, 2026. No results posted.

Sponsorhkexnews.hkDec 2, 2025, 12:00 AM

Shanghai Bao Pharmaceuticals Co., Ltd. Pipeline Update

KJ101 (Recombinant Human Chymotrypsin): Phase II trial stage for wound healing including burn injuries; expect to complete Phase II trial in 2026 H1.

NO_DECISIONDismissed95% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial (NCT07025408) is recruiting with primary completion estimated for March 2026. No results, topline readout, efficacy data, or sponsor statements on outcomes have been published as of April 2026. All sources confirm ongoing status only; primary endpoint is safety (AEs to day 35).

Found Apr 6, 2026, 2:12 PMReviewed Apr 6, 2026, 2:19 PM

Web Searchclinicaltrials.gov

Phase II Clinical Trial of KJ101 in the Treatment of Deep II Degree Burns

Recruiting. Estimated primary completion 2026-03-18. Primary endpoint: incidence and severity of AEs/SAEs via CTCAE v5.0 to day 35. Evaluates safety, efficacy, PK, immunogenicity of KJ101 for deep second-degree burn debridement.

Web Searchhkexnews.hkMar 26, 2026, 12:00 AM

Shanghai Bao Pharmaceuticals Co., Ltd. announcement

Phase II trial for KJ101 in burns initiated July 2025; expects to complete in H1 2026. No efficacy or outcome data reported. Ongoing development for wound-healing indications.

Web Searchadisinsight.springer.comJun 20, 2025, 12:00 AM

KJ 101 - Shanghai Bao Pharmaceuticals - AdisInsight

Phase II trial in burns (NCT07025408) started June 2025. No results posted. Company plans Phase III after this study.

NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM

ClinicalTrialsclinicaltrials.govJun 17, 2025, 12:00 AM

Study Details | NCT07025408 | ClinicalTrials.gov

ClinicalTrials.gov lists recruiting; primary completion 2026-03-18; hasResults=false on the latest posted update.

NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No public Phase 2 readout was found for NCT07025408. The trial is still listed as recruiting on ClinicalTrials.gov with estimated primary completion on 2026-03-18, and sponsor materials say KJ101 Phase II was initiated in July 2025 rather than reporting topline efficacy/safety results. Evidence is therefore incomplete and not readout-specific.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT07025408 | Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns | ClinicalTrials.gov

ClinicalTrials.gov lists NCT07025408 as recruiting, with estimated study start June 16, 2025, primary completion March 18, 2026, and study completion August 29, 2026.

Sponsoriren.baopharma.comDec 2, 2025, 12:00 AM

Shanghai Bao Pharmaceuticals Co., Ltd. annual report / listing document excerpt

Sponsor document says KJ101 received IND approval in February 2025 and initiated its Phase II clinical trial in July 2025; it does not report Phase II burn results.

NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No public Phase 2 readout was found for this exact trial. ClinicalTrials.gov still lists NCT07025408 as recruiting, and Bao Pharma materials say KJ101 Phase II was initiated in July 2025. With no trial-specific efficacy/safety readout, the outcome cannot be classified positive or negative.

Found Apr 1, 2026, 7:53 PMReviewed Apr 1, 2026, 7:55 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT07025408 | Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns

ClinicalTrials.gov identifies NCT07025408 as the Phase II KJ101 burn study and the current status is recruiting, indicating no completed public readout yet.

Sponsorhkexnews.hk

HKEX prospectus excerpt for Bao Pharma mentioning KJ101

Bao Pharma states it received IND approval for KJ101 in February 2025 and initiated its Phase II clinical trial in July 2025; the excerpt provides no efficacy or outcome readout for this trial.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.